VIOXX and cardiovascular events: A class effect?;VIOXX et complications cardiovasculaires: Une affaire de famille?

Revue du Rhumatisme (Edition Francaise)

Volumn 72, Issue 1, 2005, Pages 1-3

  Berenbaum, Francis ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; ROFECOXIB; VALDECOXIB;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COLON POLYP; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SELECTIVITY; EDITORIAL; ENZYME INHIBITION; HEART INFARCTION; HUMAN; LONG TERM CARE; RECTUM POLYP; RHEUMATOID ARTHRITIS;

EID: 12144268269     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2004.11.001     Document Type: Editorial

References (13)

1. C. Bombardier L. Laine A. Reicin D. Shapiro R. Burgos-Vargas B. Davis et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N. Engl. J. Med. 343 2000 1520-1528
2. F. Berenbaum Selective cyclooxygenase-2 inhibitors: Hope and facts Joint Bone Spine 67 2000 499-501
3. D. Mukherjee S.E. Nissen E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 2001 954-959
4. E. Ott N.A. Nussmeier P.C. Duke R.O. Feneck R.P. Alston M.C. Snabes et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery J Thorac Cardiovasc Surg. 125 2003 1481-1492
5. M.E. Farkouh H. Kirshner R.A. Harrington S. Ruland F.W. Verheugt T.J. Schnitzer et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial Lancet 364 2004 675-684
6. S. Tacconelli M.L. Capone M.G. Sciulli E. Ricciotti P. Patrignani The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity Curr Med Res Opin. 18 2002 503-511
7. A. Whelton COX-2-specific inhibitors and the kidney: Effect on hypertension and oedema J Hypertens 20 Suppl 6 2002 S31-S35
8. D.J. Graham D.H. Campen C. Cheetham R. Hui M. Spence Ray Wa Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective anti-inflammatory drugs In: 20th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Aout 2004 (abstract)
9. M. Mamdani P. Rochon D.N. Juurlink G.M. Anderson A. Kopp G. Naglie et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly Arch. Intern. Med. 163 2003 481-486
10. G.S. Bleumink J. Feenstra M.C. Sturkenboom B.H. Stricker Nonsteroidal anti-inflammatory drugs and heart failure Drugs 63 2003 525-534
11. J.A. Baron B.F. Cole R.S. Sandler R.W. Haile D. Ahnen R. Bresalier et al. A randomized trial of aspirin to prevent colorectal adenomas N. Engl. J. Med. 348 2003 891-899
12. F. Berenbaum NSAIDs and aspirin: Friends or foes? Joint Bone Spine 70 2003 89-90
13. M.C. Boissier Pondering the precautionary principle Joint Bone Spine 70 2003 318-320